Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.

Goodkin, David A; Zhao, Junhui; Cases, Aleix; Nangaku, Masaomi; Karaboyas, Angelo

Goodkin, David A; Zhao, Junhui; Cases, Aleix; Nangaku, Masaomi; Karaboyas, Angelo.

Afiliación

Goodkin DA; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Zhao J; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.
Cases A; IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
Nangaku M; Division of Nephrology and Endocrinology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Karaboyas A; Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA.

Am J Nephrol ; 53(5): 333-342, 2022.

Article en En | MEDLINE | ID: mdl-35462377

Asunto(s)

Anemia; Eritropoyetina; Hematínicos; Resistencia a Medicamentos; Eritropoyesis; Eritropoyetina/uso terapéutico; Hematínicos/farmacología; Hematínicos/uso terapéutico; Humanos; Diálisis Renal/efectos adversos

Palabras clave

Erythropoiesis-stimulating agents; Erythropoietin Resistance Index; Hemodialysis; Hepcidin; Hypoxia-inducible factor-prolyl hydroxylase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Eritropoyetina / Hematínicos / Anemia Límite: Humans Idioma: En Revista: Am J Nephrol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google